Short answer: Cells grown for treatment can be tested for genetic changes, but “tested” does not mean every DNA change has been ruled out. A karyotype checks chromosome number and large structural changes; studies of cultured cells show why this matters PMC5516473. Its typical resolution is about 5–10 million DNA bases, so smaller changes need other methods PMC9360565. For your treatment, ask which tests were performed and how the results relate to the cells you will receive.
Why cultured cells need checking
Growing cells in a lab involves repeated rounds of expansion. A passage is a step in which cells are transferred for further growth. Researchers track passage numbers because chromosome findings can change during culture; a result from an earlier passage does not describe every later sample PMC5516473.

In a study of bone-marrow mesenchymal stromal cells (MSCs) from ten donors, two donor lines had abnormal clonal subpopulations at passage 3, accounting for about 2–10% of examined cells. In the six lines followed at passages 3, 5, and 7, mean abnormal-karyotype percentages were 8.0%, 7.8%, and 3.4%. The differences were not statistically significant: these numbers do not establish that longer culture makes cells safer PMC5516473.
A separate study of nine bone-marrow MSC cultures found normal chromosome counts through passage 4, followed by random chromosome-number changes in seven cultures at later passages. Most disappeared at the next passage examined, but one culture showed a clonal abnormality from passages 6 to 8. Neither study establishes a universally safe passage limit or a patient’s risk of harm PMC6496525.
What genetic testing means here
This question concerns the cells intended for treatment, not a test of your inherited disease risk. It is also separate from donor infection screening, which is another part of cell-product assessment Content and review chemistry manufacturing and control cmc information human somatic cell therapy.
- Chromosome-number changes: an extra or missing chromosome, called aneuploidy.
- Structural changes: chromosome material moved, lost, or duplicated.
- Smaller DNA changes: changes below a chromosome test’s resolution, including single-letter variants.
Which tests find which changes?
These methods answer different questions. The resolution figures below describe methods, not guaranteed detection limits for every cell product. The cited comparison comes from prenatal diagnostics; the laboratory must explain its own assay’s performance PMC9360565.
| Test | What it can show | Important limit |
|---|---|---|
| G-banded karyotype | Chromosome number and large structural changes, typically around 5–10 Mb PMC9360565 | Does not rule out smaller DNA changes or rare abnormal cells. |
| FISH | Selected chromosome regions, using targeted probes 003935.htm | Only addresses the regions the probes target. |
| Spectral karyotyping (SKY) | Chromosomes distinguished by color, helping identify rearrangements PMC5516473 | Examines sampled dividing cells, not every cell in the batch. |
| Chromosomal microarray | DNA gains and losses, sometimes as small as 50–100 kb PMC9360565 | Does not reliably detect balanced rearrangements or single-letter variants. |
| DNA sequencing | Smaller sequence changes within the regions analyzed PMC9360565 | Coverage and interpretation matter; it is not a universal safety certificate. |
Mb means a million DNA bases; kb means a thousand. A conventional karyotype may examine about 20 dividing cells, whereas the SKY study used larger counts to investigate small abnormal subpopulations. Ask for the actual count rather than assuming “20” describes every test PMC5516473. Karyotyping examines chromosome size, shape, and number under a microscope 003935.htm.
What happens after an abnormal result?
Ask how a result affects the decision to release cells for treatment. FDA’s 2008 guidance for investigational somatic-cell products recommends describing manufacturing controls, cell-bank testing, and intermediate and final acceptance criteria. It is guidance for US investigational applications, not proof that a particular clinic tested your cells or that every product requires the same panel Content and review chemistry manufacturing and control cmc information human somatic cell therapy.
Acceptance limits are product-specific
The MSC study reports an International Society for Cellular Therapy suggestion to exclude cells from clinical use when two identical abnormal metaphases are found among 20 examined. That is a reported suggestion, not a universal release rule. Ask the provider to explain its acceptance criteria, the result, and how an out-of-range finding is investigated before any release decision PMC5516473Content and review chemistry manufacturing and control cmc information human somatic cell therapy.
What does a normal result leave unanswered?
- Whether changes below the test’s resolution are present.
- Whether a small abnormal subpopulation was missed in sampling.
- Whether cells at a later passage have the same findings.
- Whether the proposed treatment is safe and effective for your condition.
The first three depend on the method and sample examined PMC5516473PMC9360565. A genetic report is only one part of product assessment; FDA guidance also addresses infection testing, identity, purity, viability, and potency. It does not treat a normal chromosome result as a substitute for those assessments Content and review chemistry manufacturing and control cmc information human somatic cell therapy.
Testing is not treatment approval
Keep testing, regulatory status, and evidence of benefit separate. For US approval status, check the exact product against FDA’s licensed cellular and gene therapy products list Approved cellular and gene therapy products. When assessing a private-clinic stem-cell offer, ask which country’s authorization is being claimed. Absence from the FDA list alone does not establish the product’s status in Japan.
Under Japan’s regenerative-medicine safety framework, providers submit a provision plan and obtain the relevant certified committee’s opinion before submission. This framework is distinct from product approval; filing a plan does not itself establish efficacy for a disease En. Likewise, trial registration alone is not evidence that a treatment works; a published paper must be assessed for what it actually studied and found.
How to check the answer at consultation
A practical document-check scenario: Suppose a provider gives you a normal karyotype report. Compare its batch identifier and passage number with the proposed treatment records. If the report concerns an earlier cell bank, ask how that bank is linked to the final cells and what testing or controls cover the intervening growth. This is a checklist exercise, not a patient case or a claim of firsthand clinical experience.
Ask for a written explanation of these six points:
- The test name, sample date, batch identifier, and passage or manufacturing stage.
- The number of cells examined and the method’s stated detection limits.
- How the tested sample relates to the cells you will receive.
- The acceptance criteria, any abnormal findings, and who authorized release.
- How the cell processing center documents the link from collection through processing to delivery.
- Who can explain the report and whom to contact about follow-up or adverse effects.
Do not interpret an unexplained variant or a chromosome finding on your own. Ask the treating clinician to explain its significance and what remains uncertain before you consent.
Bring these questions to your consultation.
Ask the patient support team how to request an explanation of the testing records.
Bottom line
Cells can be tested for genetic changes, but the answer for your dose depends on the test, sample, and manufacturing records. A roughly 20-cell karyotype is not a whole-genome guarantee PMC5516473PMC9360565. Ask for a result linked to your treatment and a clear explanation of what it does—and does not—show.




